Differential expression of renal AGE-receptor genes in NOD mice: Possible role in nonobese diabetic renal disease

Kidney International

Volumn 58, Issue 5, 2000, Pages 1931-1940

  He, Ci Jiang ^a,b,c   Zheng, Feng ^a,b,c   Stitt, Alan ^a,b,c   Striker, Liliane ^a,b,c   Hattori, Masakazu ^a,b,c   Vlassara, Helen ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

Advanced glycation end product; Diabetic complications; Glycoxidation; Kidney disease; Receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MESSENGER RNA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE EXPRESSION; KIDNEY CORTEX; KIDNEY DISEASE; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033736330     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00365.x     Document Type: Article

References (36)

1. Genetic susceptibility to nephropathy in insulin dependent diabetes: From epidemiology to molecular genetics
2. Renoprotection in diabetes, genetic and non-genetic risk factors and treatments
3. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules
4. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
5. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
6. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
7. Receptor-specific induction of insulin-like growth factor-I in human monocytes by advanced glycosylation end product-modified proteins
8. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging
9. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy
10. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
11. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor
12. Evidence for the central role of glomerular growth promoters in the development of sclerosis
13. Molecular identity and cellular distribution of advanced glycation end product receptors: Relationship of p60 to OST-48 and p90-80K-H membrane proteins
14. Biochemistry, molecular biology, and genetics of the oligosaccharyl transferase
15. Purification of two distinct proteins of approximate Mr 80 000 from human epithelial cells and identification as proper substrates for protein kinase C
16. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor-stimulated cells, as 80K-H
17. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells
18. Identification of Galectin-3 as a high affinity binding protein for advance glycation end products (AGE): A new member of the AGE-receptor complex
19. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-thy1.1 antibodies
20. Expression of galectin-3 modulates T-cell growth and apoptosis
21. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors
22. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle
23. Cellular receptors for advanced glycation end products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
24. Receptor for advanced glycation end products (AGE) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
25. Advanced glycosylation end products in patients with diabetic nephropathy
26. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine
27. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
28. The genetics of the NOD mouse
29. Glomerular lesions in nonobese diabetic mouse: Before and after the onset of hyperglycemia
30. Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in non-obese diabetic mice
31. Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I
32. Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis
33. Immunochemical detection of advanced glycoxylation endproducts in vivo
34. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo
35. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor
36. Overexpression of glyoxalasein-I in bovine endothelial cells inhibits intracellular advanced glycation end product formation and prevents hyperglycemia-induced increases in macromolecular endocytosis